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Calcitriol modulates in vivo and in vitro cytokine production: A
role for intracellular calcium.
Background. Several immunomodulatory properties of calcitriol
are currently known, however, only little information is available
regarding the in vivo and in vitro effects of calcitriol on cytokine
production in chronic renal failure.
Methods. To study the in vitro effect of calcitriol on lipopoly-
saccharide (LPS)-induced cytokine production, peripheral blood
mononuclear cells (PBMC, 2.5 ml/ml) from 12 chronic dialytic
(HD), 15 undialyzed chronic renal failure (CRF) patients and 10
normal subjects (N) were incubated at 37° for 12 hours with 100
ng of LPS (E. coli and P. maltofilia). Increasing doses of calcitriol
from 10210 to 1029 M were added and cell associated TNF-a and
IL-1b were determined by immunoreactive tests after three
freeze-thaw cycles. The intradialytic TNF-a and IL-1b production
were evaluated in vivo in 12 HD patients before and after three
months of intravenous calcitriol treatment (6 mg/week). Intracel-
lular calcium [Ca11]i was determined on PBMC with a cytofluo-
rimetric assay using FLUO-3 AM as the indicator.
Results. In vitro, TNF-a increased from 3.6 6 1.9 pg/cell to
1797 6 337 in N, from 4.5 6 1.7 to 1724 6 232 in CRF and from
3.4 6 2.3 to 1244 6 553 in HD after the LPS stimulus. The
production of TNF-a was inhibited by calcitriol in a dose-
dependent manner [LPS 1 Vit.D3 100 ng, 2.9 6 2.1 in N, 3.7 6 1.9
in CRF and 3.4 6 1.7 in HD; LPS 1 Vit.D3 50 ng, 263 6 296 (N),
6.73 6 11 (CRF), 38 6 28 (HD); LPS 1 Vit.D3 25 ng 5 873 6 583
(N), 325 6 483 (CRF), 588 6 507 (HD); LPS 1 Vit.D3 12.5 ng,
954 6 483 (N), 912 6 510 (CRF), 875 6 527 (HD)]. Comparable
data were observed on IL-1b production. In vivo, the intradialytic
TNF-a increase (from 8.5 6 2.3 to 19 6 5.6 pg/2.5 3 106 cell)
during hemodialysis was markedly reduced after calcitriol therapy
(from 6.6 6 3.1 to 11 6 4.7). [Ca11]i decreased from 105 6 25 to
72 6 18 nM (P , 0.05) and a positive correlation between cytokine
levels and [Ca11]i was found (r 5 0.79; P , 0.001).
Conclusions. The in vitro increase of cell-associated cytokine
after LPS challenge was inhibited by calcitriol in a dose-depen-
dent manner. These data suggest a possible in vivo modulatory
effect of calcitriol therapy on cytokine production in hemodialysis.
In recent years it has become apparent that 1,25-dihy-
droxyvitamin D3 [1a(OH)2D3], in addition to its well
known role in mineral and skeletal homeostasis, regulates
the differentiation, growth and the function of a broad
range of cells, including the cells of the immune system [1,
2].
A major contribution towards the appreciation of the
wider biological role of 1,25-dihydroxyvitamin D3 was
provided by the elucidation of its mechanism of action.
Calcitriol exerts its effects via a specific vitamin D receptor
(VDR), a member of the superfamily of steroid/thyroid/
vitamin A hormone receptors [3], leading to gene regula-
tion mediating various biological responses.
Once bound to the hormone the receptor associates with
specific recognition sequences, called vitamin D responsive
elements (VDRE), which are present in the promoter
region of target genes and are involved in regulating their
transcription [4].
Receptors for calcitriol are not confined to the classical
target tissues (intestine, bone, kidney, parathyroid glands)
and other organs with known calcium transport function
(mammary glands, placenta), but also can be found in a
variety of “non-classical” target tissues such as monocytes
and activated B and T lymphocytes [5, 6].
Following these observations it is well established that
calcitriol has immunomodulatory capacities in vivo and in
vitro [7]. Vitamin D-deficient animals and humans have a
higher risk of infection, probably related to deficient mac-
rophage function [8], whereas the monocyte/macrophage
differentiation and activity is enhanced by exposure to
1a(OH)2D3 [9]. The monocyte function of antigen presen-
tation is also decreased [10], and it is well known that
monocytes are functionally modulated by interleukins
(IL-1) and tumor necrosis factor-alpha (TNF-a).
In fact, calcitriol inhibited the production of TNF-a by
normal human monocytes stimulated with either interferon
or phorbol esters [11], while in the human myelomonocytic
cell line, U-937, calcitriol induced a marked enhancement
of LPS-stimulated IL-1b messanger RNA levels [12].
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However, little information is available regarding the
effect of calcitriol on the cytokine response in chronic renal
failure (CRF), a well known condition of vitamin D3
deficiency [13–15].
Cytokine production is known to depend on intracellular
calcium ([Ca11]i) [16, 17]; moreover, it has also been
shown that IL-2 production by T cells is stimulated by a rise
in intracellular calcium [18]. Massry and Fadda described
that leukocytes of CRF patients and those treated with
hemodialysis have elevated basal levels of [Ca11]i, reduced
adenosine 59-triphosphate (ATP) content and impaired
phagocytosis [19]. These derangements were related to
secondary hyperparathyroidism. These authors also postu-
lated that chronic elevation in [Ca11]i in T cells could
interfere with the magnitude of the rise in [Ca11]i in
response to stimulation of T cells, thus impairing the
production of IL-2.
Since [Ca11]i seems pivotal in regulating cytokines se-
cretion by monocytes from normal subjects and uremic
patients, the present study was undertaken in order to
establish a direct relationship between in vitro data and
clinical effects.
To this aim, we evaluated the effects of calcitriol on the
in vivo and in vitro cytokine production in chronic uremic
patients and related it to the variations in [Ca11]i.
METHODS
In vitro studies
Patients. The study population consisted of 12 (8 males
and 4 females) patients (HD) undergoing regular mainte-
nance hemodialysis with a mean age of 53 6 12 years and
a mean dialytic age of 42 6 13 months. Fifteen patients
(CRF) suffering from chronic renal failure with a mean
creatinine clearance of 16 6 8 ml/min (range 8–32 ml/min)
were also studied. The original nephropathy was chronic
glomerular nephritis (N 5 9), chronic interstitial nephritis
(N 5 4) and polycystic kidney disease (N 5 2). Ten sex- and
age-matched healthy adult volunteers (N) with normal
renal function served as the controls.
None of these subjects received calcitriol replacement
therapy or drugs known to influence the immune system for
at least two months before the study.
Cell isolation. Monocytes enriched PBMC were isolated
by Ficoll (Histopaque-1077, Sigma-Aldrich Co., Ltd., UK)
gradient centrifugation from blood that was withdrawn into
heparinized (10 U/ml) syringes. Cells were washed in HBSS
(Sigma-Aldrich Co., Ltd., UK), counted and cultured in
RPMI 1640 medium (Sigma-Aldrich Co., Ltd., UK) sup-
plemented with 10% heat-inactivated fetal calf serum
(FCS), glutamine and antibiotics in 24-well plates (Costar,
Cambridge, MA, USA) at 37°C in an atmosphere contain-
ing 5% CO2.
RPMI contained no detectable amount of endotoxin as
assessed by LAL test. Purity of monocytes fraction was
confirmed by FACS (Becton-Dickinson, San Jose, CA,
USA) analysis using anti-CD14 monoclonal antibody. Cells
were incubated with lipolysaccharides (LPS) (kind gift of
Dr. G. Lonnemann, Hannover, Germany) from Escherichia
coli and Pseudomonas maltofilia 100 ng/ml and simulta-
neously with increasing doses of calcitriol (Sigma-Aldrich
Co., Ltd., UK) (from 10210 M to 1029 M) for 12 hours.
Monocytes were incubated in the following conditions:
alone, with LPS alone, with LPS and calcitriol 4 3 1029 M,
with LPS and calcitriol 2 3 1029 M, with LPS and calcitriol
1 3 1029 M, and with LPS and calcitriol 5 3 10210 M. Cell
viability (.95%) was assessed by the gamma-eosin method.
Cytokine assays. After the incubation, cells were lysed by
three freeze (240°C) and thawing (37°C) cycles. Intracel-
lular cytokine concentrations were determined by ELISA
(for IL-1b, Immunotech, Marseille, France and for TNF-a
Medgenix Diagnostics, Brussels, Belgium). The percent of
intra- and inter-assay variability were respectively 11.9%
and 12.5% for TNF-a, and 10.9% and 10.4% for IL-1b. The
sensitivity thresholds (pg/ml) were 5.5 for IL-1b and 3.7 for
TNF-a. Samples were assayed in duplicate. Results were
normalized to the monocytes concentration of 2.5 3 106
monocytes and expressed in pg/2.5 3 106 monocytes.
In vivo studies
Twelve patients (8 males and 4 females) with end-stage
renal failure were included in the study after informed
consent. Their ages ranged from 41 to 69 years (mean 55 6
12 years). They did not receive corticosteroids, NSAIDs,
calcium blockers, anticonvulsivants or vitamin D derivates.
All patients were on a soft hemodiafiltration dialysis pro-
gram for an average of 65 months (range 12 to 71). They
were dialyzed three times a week with a polyacrylonytrile
membrane (1.8 m2) with a bicarbonate bath of 35 mEq/
liter. Blood flow was 350 ml/min and reinfusion flow (3
liters/hour) of a buffered lactate solution of 42 mM.
The type of membrane and the dialysis technique were
not changed during the study period and there were no
intercurrent diseases. No patient had a history of immune
dialysis-related reaction. The basal secretion of cytokine
was determined from blood samples obtained before and
after a midweek dialytic session. Blood was treated as for
the above-described in vitro experiments. Blood samples
were immediately processed (average time interval be-
tween blood sampling and PBMC purification less than 30
minutes) and the cell suspensions were stored at 270° until
assayed for intracellular cytokine determination.
After the baseline studies, patients were started on
intravenous calcitriol treatment (Calcijex, Roche) 2 mg at
the end of each dialysis session. Three months later blood
was again obtained for intracellular cytokine assay.
Biochemical assays
Ionized calcium (iCa) was measured in serum samples
obtained under anaerobic conditions with a Nova 7 Ana-
lyzer. The normal range in our laboratory is 1.10 to 1.22
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mM, CV 1.5%. Intact PTH (iPTH) was measured with an
IRMA (Nichols Institute) utilizing two different polyclonal
antibodies, purified by affinity chromatography, specific for
the 39-84 and 1-34 regions. The normal range was 20 to 60
pg/ml and the CV 5.7%. Serum levels of calcitriol were
measured by a radioreceptorial method (RRA; Nichols).
Plasma samples were eluted on C18OH column after ace-
tonitrile extraction and then dosed in duplicate. The nor-
mal range was 20 to 46 pg/ml; the calculated intra-assay
coefficient of variation was 10% and the interassay coeffi-
cient was 14%. Total calcium, phosphate, alkaline phospha-
tase were measured by standard methods (Technicon Auto
Analyzer).
Intracellular calcium
[Ca11]i was determined on PBMC in all in vivo and in
selected in vitro experiments. The isolated PBMC (2.5 3
106 cells/ml) were incubated with HBSS containing 0.5%
BSA at final concentration of 10 microM Fluo-3 Acetoxym-
ethyl Ester (Molecular Probes, Inc.; solubilized in DMSO-
Aldrich) for 40 minutes at 37°C.
Cells were centrifuged (400 g for 10 min), resuspended in
HBBS containing 0.5% BSA and kept at room temperature
for one hour under constant linear agitation allowing
hydrolysis of the ester to yield the active calcium indicator.
Using this method, cells showed no evidence of dye com-
partmentalization and could be used for up to three hours
with only minimal leakage of the Fluo-3 dye. Intracellular
calcium was measured with a cytofluorimeter (Cytofluor
2300; Millipore) at an excitation wavelength of 506 nm and
emission wavelength of 526 nm evaluating the maximum
fluorescence (Fmax) after the addition of calcium chloride
and ionomicine, an ionofore able to open calcium channels.
Later, manganese chloride was added, and this salt binds
Fluo 3 AM with a higher affinity than calcium, thus
determining the minimum fluorescence (Fmin).
Intracellular calcium was calculated using the Grynk-
iewicz, Poenie and Tsien equation:
[Ca11]i 5 Kd 3 (F 2 Fmin)/(Fmax 2 F)
and the dissociation constant (Kd) for Fluo-3 AM was
assumed to be 400 nM. Intracellular calcium levels in resting
PBMC have been evaluated in our laboratory in normal
subjects, chronic pre-dialytic renal failure and dialytic
patients.
Statistics
Results are expressed as means 6 standard deviation.
Results were evaluated by one way analysis of variance,
Student’s t-test for paired and unpaired data, and the linear
correlation analysis. Values of P , 0.05 were regarded as
statistically significant.
RESULTS
In vitro studies
The average values for cell-associated TNF-a and IL-1b
in normal control subjects (N), in chronic pre-dialytic
(CRF) and dialytic (HD) patients are shown in Table 1.
The spontaneous production of these cytokine was similar
in patients and controls and was not affected by vitamin D
plasma levels (Table 1). Stimulation of PBMC by LPS
resulted in a great increase of TNF-a and IL-1b in normal
patients and in CRF patients, but a reduced production in
HD patients (Figs. 1 and 2). In fact, TNF-a increased from
3.6 6 1.9 pg/2.5 3 106 cells to 1797 6 337 pg/2.5 3 106 cells
in N, from 4.5 6 1.7 pg/2.5 3 106 cells to 1724 6 232
pg/2.5 3 106 cells in CRF patients and from 3.4 6 2.3 to
1244 6 553 pg/2.5 3 106 cells in HD patients. IL-1b
increased from 7.3 6 4.5 pg/2.5 3 106 cells to 2720 6 559
pg/2.5 3 106 cells in N, from 5.2 6 3.9 pg/2.5 3 106 cells to
2480 6 498 pg/2.5 3 106 cells in CRF and from 13.2 6 7.9
to 1790 6 431 pg/2.5 3 106 cells in HD. The simultaneous
addition of increasing doses of calcitriol from 10210 to 1029
M to these cultures induced a dose-dependent inhibition of
TNF-a and IL-1b production in PBMC stimulated by LPS
in all groups (Figs. 1 and 2). It should be noticed, however,
that no differences were observed in TNF-a and IL-1b
production when PBMC were incubated with different
doses of calcitriol without LPS.
In vivo studies
The 12 HD patients in this study underwent hemodialysis
without calcitriol supplementation. TNF-a and IL-1b pro-
duction were assayed at the start and at the end, and after
a single midweek hemodialysis session before and after
three months of calcitriol therapy.
Calcitriol plasma levels increased from 23 6 4.7 pg/ml to
45 6 6.5 pg/ml (P , 0.05) after three months of calcitriol
supplementation. All biochemical data before and after the
three months of calcitriol therapy are reported in Table 2.
The basal TNF-a and IL-1b intradialytic increases were
significantly reduced after calcitriol therapy (Figs. 3 and 4).
Table 1. Basal production of tumor necrosis factor-a (TNFa),
interleukin-1b (IL-1b) and 1,25 vitamin D3 plasma levels in normal (N),
pre-dialytic (CRF) and hemodialytic patients (HD) by human
peripheral blood cells (PBMC)
Groups
TNF-a IL-1b 1,25 (OH)2D3
pg/mlpg/2.5 3 106 cells
N 3.6 6 1.9 7.3 6 2.1 65 6 5.8
CRF 4.5 6 1.7 5.2 6 1.9 30 6 4.3
HD 3.4 6 2.3 13.2 6 3.6 18 6 5.6
The spontaneous production of cell-associated cytokines was similar in
patients and controls and was not affected by 1,25 vitamin D3 plasma
levels (normal values 20–46 pg/ml).
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Intracellular calcium
The mean 6 SD values of [Ca11]i resulted 105 6 13 nM
for normal subjects, 148 6 17 nM in CRF patients and
125 6 7 nM in HD patients at the start of dialysis.
Intracellular variations following the in vitro LPS and
calcitriol challenge are reported in Figure 5.
The intracellular calcium concentration of isolated
monocytes from hemodialysis patients before and after
three months of calcitriol intravenous therapy (in vivo
studies) is reported in Table 2. A positive correlation
between intracellular calcium and cytokine expression was
found (Fig. 6) (r 5 0.79; P , 0.001).
DISCUSSION
The backtransport of bacterially-derived material from
the dialysate to the blood compartment, which inevitably
occurs in several dialytic techniques, has been implicated
for the activation of PBMC and subsequent cytokine re-
lease. Cytokine production is currently implicated in
chronic dialysis-related morbidity, such as amyloidosis and
muscle wasting [20].
Fig. 1. In vitro studies. TNF-a production in
PBMC stimulated by LPS (100 ng/ml for 12
hours). The simultaneous addition of different
doses of calcitriol to these cultures induced a
significantly dose-dependent inhibition of TNF-
a production in all groups. Symbols are: (h)
normal subjects; (
  
  
  ) chronic predialytic; (n)
hemodialysis patients. Bars are the means 6 1
SD of fifteen experiments performed in
triplicate (*P , 0.05).
Fig. 2. In vitro studies. IL-1b production in
PBMC stimulated by LPS (100 ng/ml for 12
hours). The simultaneous addition of different
doses of calcitriol to these cultures induced a
significantly dose-dependent inhibition of IL-1b
production in all groups. Symbols are: (h)
normal subjects; (
  
  
  ) chronic predialytic; (n)
hemodialysis patients. Bars are the means 6 1
SD of fifteen experiments performed in
triplicate (*P , 0.05).
Fig. 3. In vivo studies. TNF-a production by PBMC of 12 hemodialytic
patients assayed at the start (h) and at the end ( ) of a single midweek
hemodialysis session, before and after three months of calcitriol therapy.
The basal intradialytic increase was significantly reduced (*P , 0.05). Bars
are the means 6 1 SD of 12 dialyzed uremic patients.
Table 2. In vivo studies: Biochemical data before and after 3 months of
calcitriol therapy (plasma concentrations)
Basal 3 months
Total Ca11 mg/dl 9.0 6 1.1 9.8 6 1.7
Ionized Ca11 mM 1.15 6 0.2 1.21 6 0.29
Phosphate mg/dl 3.7 6 1.0 5.0 6 1.5a
iPTH pg/ml 182 6 45 150 6 64
ALP U/liter 172 6 25 168 6 31
Intracellular Ca11 nM 105 6 25 72 6 18a
1,25 vitamin D3 pg/ml 18 6 4.7 45 6 6.5
a
Biochemical data of 12 hemodialytic patients undergoing HDF before
and after 3 months of calcitriol therapy (i.v. 2 mg three times a week) are
presented. 1,25 Vitamin D3 and plasma phosphate increased with a
significant reduction of intracellular calcium.
a P , 0.05
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The present study demonstrates that calcitriol in vitro
inhibits the LPS-induced production of TNF-a and IL-1b
in both uremic patients and normal subjects in a dose-
dependent manner. The concentrations of calcitriol used in
the in vitro experiments were within the physiologic range.
Therapeutic doses of calcitriol are also able to induce a
marked decrease of cytokine production in vivo during HD.
Contradictory findings on the effects of calcitriol on the
accessory function of macrophages have been reported [9,
10, 21]. This confusion may partly be due to the use of cells
with different differentiation/maturation status such as
monocytic leukemia lines, where calcitriol induces differ-
entiation of the very immature leukemic cells towards
mature monocytes/macrophages [22]. In fact, the calcitriol-
induced modifications of interleukin secretion are variable
and may depend on the differentiation/maturation status of
target cells [23] and on the different concentrations of
calcitriol used.
Bhalla, Amento and Krane found that calcitriol en-
hanced the release of IL-1 by human monocyte-macroph-
ages cultured for six days [24]. On the other hand, Tsoukas
et al observed that 1028 M of calcitriol inhibited the release
of IL-1, as well as the levels of cell-associated and mem-
brane-associated IL-1, in human monocytes co-cultured
with T lymphocytes and stimulated with phytohemoagglu-
tinin for three days [25].
Few data are available about the influence of calcitriol on
the production of TNF-a. Yousefi et al found a calcitriol-
induced decrease in the production of TNF-a by PBMC
[26] but Rook et al reported an increased LPS-induced
secretion of TNF-a by human monocytes previously cul-
tured in the presence of 1027 of calcitriol for four days [27].
On the other hand, Steffen et al found that 5 3 1027 of
calcitriol enhanced the transcription of the TNF-a mRNA
in HL-60 cells [28], and no significant effects were found on
unstimulated or LPS-stimulated PBMC by Zarrabietia et al
[29].
Our data indicate a dose-dependent in vitro inhibition of
the LPS-induced IL-1b and TNF-a production in PBMC
from normal and uremic subjects incubated with physio-
logic doses of calcitriol (Figs. 1 and 2).
Several lines of evidence support an in vivo immuno-
stimulating role of 1,25(OH)2D3; thus, vitamin D-defi-
ciency states such as in rickets are associated with defective
Fig. 4. In vivo studies. IL-1b production by PBMC of 12 hemodialytic
patients assayed at the start (h) and at the end ( ) of a single midweek
hemodialysis session, before and after three months of calcitriol therapy.
The basal intradialytic increase was significantly reduced (*P , 0.05). Bars
are the means 6 1 SD of 12 dialyzed uremic patients.
Fig. 5. In vitro studies. Intracellular calcium ([Ca11]i) concentration in
PBMC of normal subjects (h), chronic predialytic (
  
  
  ) and hemodialytic
patients (n) as the control. Intracellular calcium was significantly in-
creased following LPS stimulation (100 ng/ml for 12 hours; *P , 0.05) in
all groups. The simultaneous addition of calcitriol (at a dose of 2.5 3 10210
M) was able to prevent [Ca11]i increase. Bars are the means 6 1 SD of ten
experiments performed in duplicate in each group of subjects.
Fig. 6. In vivo studies. (A) Significant (P , 0.001) correlation between
IL-1b levels and [Ca11]i on PBMC of 12 hemodialytic patients assayed at
the start of a single midweek hemodialysis session before calcitriol therapy
(basal). (B) Significant (P , 0.001) correlation between IL-1b levels and
[Ca11]i on PBMC of 12 hemodialytic patients assayed at the start of a
single midweek hemodialysis session after three months of calcitriol
therapy.
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[30] rather than enhanced immunity, and cellular immunity
is impaired in end-stage renal disease where production of
calcitriol by the kidney has virtually ceased. Based on the
discovery of major effects of calcitriol on immune cells it
became clear that calcitriol might be an interesting mole-
cule for immunomodulation in vivo. Several groups have
demonstrated impressive effects of calcitriol and its analogs
in different animal models for autoimmunity and organ
transplantation [31, 32].
Recently, Mathieu et al demonstrated that additive
inhibition of T-cell proliferation and cytokine production is
induced by a combination of calcitriol with more classical
inhibitors of T-cell function, such as cyclosporine A, FK506
and rapamycin [33].
Cooperative effects between calcitriol and classical im-
mune suppressants have been confirmed in several in vivo
models of autoimmunity and tissue transplantation. In
experimental allergic encephalitis the murine model for
multiple sclerosis, Lemire and Archer demonstrated that
calcitriol itself not only prevented disease induction by
mielin basic protein in native animals, but also abrogated
the transfer of the disease by mielin basic protein-specific
T-cell clones isolated from presensitized animals [34].
Finally, experimental lupus erythematosus in MRL/I mice
could be prevented by calcitriol and several of its analogs.
Proteinuria and histological lesions could be improved.
In this article we suggest a possible in vivo modulatory
role of the cell-associated TNF-a and IL-1b increase
induced by hemodialysis. In fact, in our patients the basal
TNF-a and IL-1b intradialytic increases were significantly
reduced after calcitriol therapy.
Cytokine production may be modulated by calcitriol
either as a result of its direct interaction with monocytes or
indirectly through its effect on calcium and PTH metabo-
lism.
It has been reported that repression of IL-2 gene tran-
scription by 1,25 vitamin D occurs via a VDR-dependent
inhibition of the NFATp/AP-1 complex formation [35]. In
addition, it has also been described that 1,25 vitamin D may
suppress the transcriptional activation of p35 and p40 genes
in IL-12 synthesis [36].
Carozzi et al found a dose-related increase in cytokine
production by peritoneal macrophages following their in-
cubation with various concentrations of calcium [37]. We
observed a high correlation between cytosolic calcium of
isolated monocytes and cytokine expression (r 5 0.79; P ,
0.001).
Cytosolic calcium was measured according to Tsien et al
[38, 39] using Fluo 3 AM as a long wavelength indicator for
tracing intracellular calcium. Fluo 3 AM exhibits a typical
fluorescein spectra with an excitation at 506 nm and
emission at 526 nm. The detection sensitivity of Fluo 3
fluorescence is generally 35 to 50 times greater than
Quin-2, which reduces the indicator loading concentration
required with a resultant decrease in Ca11 buffering.
In conclusion, the in vitro increase of cell-associated
cytokine production after the LPS challenge is dose-depen-
dently inhibited by calcitriol. A modulatory effect of calcit-
riol therapy on the in vivo cytokine production in patients
undergoing HD may also be suggested.
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